NRP409 is a triiodothyronine (T3) hormone, being investigated by New River Pharmaceuticals as a treatment for patients with primary hypothyroidism.
- Mechanism
- Curator reviewed
NRP409 is presumed to work like the endogenous thyroid hormone thyroxine (T4, a tetra-iodinated tyrosine derivative). In the liver and kidney, T4 is converted to T3, the active metabolite. In order to increase solubility, the thyroid hormones attach to thyroid hormone binding proteins, thyroxin-binding globulin, and thyroxin-binding prealbumin (transthyretin). Transport and binding to thyroid hormone receptors in the cytoplasm and nucleus then takes place. Thus by acting as a replacement for natural thyroxine, symptoms of thyroxine deficiency are relieved.
- Primary indication
- For use in treatment of hypothyroidism.Curator reviewed
- Code names
- NRP409
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with NRP409, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account